The ROADS Clinical Study
For Patients with Newly Diagnosed Metastatic Brain Tumors
If you or someone you know have been diagnosed with a metastatic brain tumor, you should be aware of the opportunity to participate in the ROADS Clinical Study. This important clinical study compares 2 FDA-cleared radiation treatments that are proven safe: GammaTile Therapy and stereotactic radiotherapy (SRT). The ROADS Clinical Study is enrolling now at participating hospitals across the country.
Placed at the time of brain tumor–removal surgery, GammaTile Therapy immediately begins delivering targeted radiation to the area where the tumor was removed, limiting radiation exposure to healthy tissue.
SRT is a precise form of external beam radiation therapy (EBRT) that is targeted directly at the brain tumor to limit radiation exposure to healthy tissue. It is typically completed on an outpatient basis in a series of 1-5 treatments.
Study participants will be randomly divided into 2 treatment groups: brain tumor removal surgery + GammaTile Therapy and brain tumor removal surgery + SRT. Following brain tumor removal surgery, clinical study participants will receive either GammaTile Therapy or SRT to the area where the tumor was.
Study participants in both groups may have additional brain tumors that may not be suitable for surgical removal. These remaining brain tumors will be treated with SRT.
As a ROADS Clinical Study participant, you will receive a proven safe, effective treatment, and your care will be closely monitored by a physician and the medical research team. In addition, you’ll be making an important contribution to future patients with brain tumors, by helping to ensure they also receive the best possible treatment.
The End Brain Cancer Initiative
16150 NE 85th St, Suite #201
Redmond, WA 98052
Scan or click the QR code to download the App now!
- Trials & Studies
- New Research
- Patient & Caregiver Resources
- Disease Information
- Meetings & Events
- And More!